Pursuing Novel Ideas
Pioneering Intravesical Therapies
Lipella Pharmaceuticals Inc is
a development-stage biotechnology company dedicated to improve patient
care by developing novel products which target intravesical therapy,
which is a method of providing local treatments directly to the urinary
bladder lumen via urethral catheterization. Our therapeutic focus
include Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS),
Overactive Bladder (OAB), and Superficial Bladder Cancer.
Lipella believes our theraputic focus represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of our core products.
Lipella applies a familiar technology, liposomes, to a novel target, the urinary bladder. Lipella’s lead product is the first liposomal therapy for bladder irritation. Lipella’s liposomal intravesical instillation is already gaining broad appeal, offering a real solution to many people who suffer from IC and OAB who otherwise have no adequate treatment options.